Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Transplant Recipient

Tundra lists 4 Transplant Recipient clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07006831

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.

Gender: All

Ages: 18 Years - Any

Updated: 2025-12-17

5 states

Kidney Disease
Kidney Transplant
Transplant Recipient
+3
RECRUITING

NCT01062581

University of Minnesota Transplant Registry

Under Transplant Information Services (TIS), the University of Minnesota Transplant Registry (UMTR) will serve as the repository for core research data.

Gender: All

Updated: 2025-03-24

1 state

Transplant Recipient
Transplant Donation
ENROLLING BY INVITATION

NCT06874920

Outcomes of Empiric Antibiotic Therapy Based on Hospital Antibiograms in Organ Transplant Recipients with Bacteraemia

The purpose of this observational study is to examine how using the hospital cumulative antibiogram to guide empirical antibiotic therapy affects outcomes in patients with bloodstream infections who have undergone solid organ transplants. The key question is: does the use of a hospital cumulative antibiogram reduce mortality and improve outcomes in these patients?

Gender: All

Ages: 18 Years - Any

Updated: 2025-03-13

Bacteremia
Transplant Recipient
ACTIVE NOT RECRUITING

NCT05410496

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection. The aim of this prospective cohort study is to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.

Gender: All

Ages: 20 Years - Any

Updated: 2025-01-09

1 state

Safety Issues
Chronic Hepatitis B
Transplant Recipient